Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biodynamics

This article was originally published in The Gray Sheet

Executive Summary

Completes a $6.2 mil. equity funding via the issuance of 560,000 shares of series B preferred stock in exchange for $2 mil. in cash and the retirement of $4.2 mil. in convertible debentures. The Tampa, Florida-based manufacturer of specialty surgical products and provider of tissue processing services says the cash funds will be used for the completion of a new U.S. tissue processing facility. Each share of the series B preferred stock will entitle its holder "to receive 8.5% cumulative cash dividends, payable quarterly, and to convert into common stock at $1.10 per share" the company says. As a result of the financing, Biodynamics" series A convertible preferred shareholders will be able to convert their stock into common stock at $1.25 per share. The firm retains an option to redeem the series B stock after three years for 120% of its issue price
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel